South Africa proposes limiting drug patent extensions

04/23/2013 | PharmaLive.com

South Africa has announced plans to limit the ability of drug firms to win patent extensions for brand-name drugs by changing or modifying them in minor ways. Critics allege that such extensions block patients from receiving cheaper and more affordable versions of life-saving medications for such conditions as HIV/AIDS. The South African move comes barely a month after India rejected a patent extension request from Novartis for its best-selling Gleevec cancer treatment.

View Full Article in:

PharmaLive.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT